权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

GMPS-GMPR axis melanoma progression and therapy

GMPS-GMPR轴黑色素瘤进展和治疗

基本信息

批准号：
9920697
负责人：
Mikhail Nikiforov
金额：
$ 38万
依托单位：
WAKE FOREST UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-05-15 至 2023-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9920697
关键词：
Affect Anabolism Area BRAF gene Cell Line Cells Clinical Data Dissociation Dose Drops Enzymes Eph Family Receptors Event Extracellular Matrix Family GMP reductase GMP synthase GTP Binding GTP-Binding Proteins Goals Growth Guanosine Monophosphate Guanosine Triphosphate Guanosine Triphosphate Phosphohydrolases High Pressure Liquid Chromatography Human IMPDH2 gene Immune response Immunocompetent Immunocompromised Host Immunosuppressive Agents In Vitro Invaded Length MEKs Malignant Neoplasms Measures Mediating Melanoma Cell Metabolism Metastatic Melanoma Methods Modeling Monitor Mus Nature Neoplasm Metastasis Patients Peptides Pharmaceutical Preparations Phenocopy Phenotype Phosphorylation Phosphotransferases Physiological Protein Tyrosine Kinase Proteins Purine Nucleotides RHOA gene RHOC gene Regulation Reporting Resistance Resistance development Ribavirin Role Testing Therapeutic Time Tumorigenicity Variant Visualization Xenograft procedure anti-hepatitis C cancer cell chemotherapeutic agent chemotherapy crosslink enzyme biosynthesis experimental study gain of function guanylate immunoregulation improved in vivo inhibitor/antagonist liquid chromatography mass spectrometry melanocyte melanoma molecular marker mutant novel outcome forecast overexpression pre-clinical prognostic value programmed cell death ligand 1 recruit restoration rho rho GTP-Binding Proteins screening sensor standard of care tumor xenograft tumorigenesis xanthosine monophosphate

项目摘要

Malignant melanoma is one of the most aggressive types of human cancers. Its ability to metastasize in combination with its notorious resistance to conventional chemotherapeutical agents makes melanoma extremely difficult to cure. Consequently, the median survival of patients with metastatic melanoma is only 8.5 months. The acquisition of invasion capability, which occurs already in primary melanomas, is a prerequisite for metastasis and is considered a critical event associated with poor prognosis. We have recently demonstrated that expression of guanosine monophosphate reductase (GMPR), an enzyme involved in the de novo biosynthesis of purine nucleotides, was downregulated at the invasive stages of human melanoma. Loss- and gain-of-function experiments revealed that GMPR suppresses the ability of melanoma cells to form invadopodia, degrade extracellular matrix, invade (in vitro and in vivo), and grow as tumor xenografts. We further demonstrated that depletion of guanosine monophosphate synthase (GMPS), a functional antagonist of GMPR, decreases active (GTP-bound) RAC1, RHOA and RHOC. We hypothesized that GMPS, GMPR, and perhaps other guanylate biosynthesis enzymes, regulate the activity of the above RHO-GTPases via modulation of GTP levels in the vicinity of these RHO-GTPases. This hypothesis will be tested in Specific Aim 1. We demonstrated that the activity of GMPR can be regulated by phosphorylation. Unbiased in vitro kinase screening identified several kinases as potential candidates for GMPR phosphorylation. Modulation of GTP levels has never been considered as a mechanism of regulation of invasion by any kinase. Therefore, in Specific Aim 2, using functional approaches, we will test candidates' ability to regulate GTP levels, RHO- GTPase activity and cell invasion in a GMPR-dependent manner. Currently, no efficient chemotherapy exists for melanoma patients with wildtype BRAF and mutant NRAS. Survival of patients with mutant BRAF was improved by the introduction of its inhibitor vemurafenib (VEM), however rapidly developing resistance circumvents VEM efficacy. Although the mechanisms of such resistance vary, several melanoma cell lines independently selected for VEM resistance possessed increased invasion ability. We demonstrated that several GTP-depleting agents can significantly affect melanoma xenograft growth in immunocompromised and immunocompetent mice. Therefore, in Specific Aim 3, we will evaluate the efficacy of one of such agents alone or in combination with existing anti-melanoma therapy in several preclinical melanoma models.

恶性黑色素瘤是最具侵袭性的人类癌症之一。它的转移能力